Recordati SpA (Recordati SpA) Debt-to-Equity : 1.07 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Recordati SpA Debt-to-Equity?

Recordati SpA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $497 Mil. Recordati SpA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,476 Mil. Recordati SpA's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,839 Mil. Recordati SpA's debt to equity for the quarter that ended in Dec. 2023 was 1.07.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Recordati SpA's Debt-to-Equity or its related term are showing as below:

RCDTF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.38 Med: 0.77 Max: 1.11
Current: 1.07

During the past 13 years, the highest Debt-to-Equity Ratio of Recordati SpA was 1.11. The lowest was 0.38. And the median was 0.77.

RCDTF's Debt-to-Equity is ranked worse than
86.57% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs RCDTF: 1.07

Recordati SpA Debt-to-Equity Historical Data

The historical data trend for Recordati SpA's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recordati SpA Debt-to-Equity Chart

Recordati SpA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.92

0.83

0.72

1.11

1.07

Recordati SpA Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															1.11	0.96	1.16	1.05	1.07

Competitive Comparison of Recordati SpA's Debt-to-Equity

For the Drug Manufacturers - General subindustry, Recordati SpA's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Recordati SpA's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Recordati SpA's Debt-to-Equity falls into.

Recordati SpA Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Recordati SpA's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(496.929	+	1475.699)	/	1839.032
	=	1.07

Recordati SpA's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(496.929	+	1475.699)	/	1839.032
	=	1.07

Recordati SpA (OTCPK:RCDTF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Recordati SpA Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Recordati SpA's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Recordati SpA (Recordati SpA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Recordati SpA (OTCPK:RCDTF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

RICFY:USA REC:Italy RECm:UK 0KBS:UK RER1:Germany

Address

Via Matteo Civitali 1, MIlan, ITA, 20148

Website

https://www.recordati.com

Recordati SpA is a drug manufacturing company that focuses on specialty pharmaceuticals. The company produces and promotes medicines globally that focus on primary-care therapies and rare diseases. Recordati uses strategic partnerships as part of its long-term growth. The vast majority of the company's revenue is generated in Italy, followed by the United States, France, and Germany. Recordati reports two operating segments: Specialty and Primary care and Rare diseases. The bulk of the company's profit is derived from its specialty and primary care segment, which includes the production of active ingredients.

Recordati SpA (Recordati SpA) Headlines

From GuruFocus

Recordati: Positive Results From the Phase III LINC-3 Study of Isturisa® (osilodrostat) for the Treatment of Cushing's Disease Published in Lancet Diabetes & Endocrinology

By Business Wire Business Wire • 07-28-2020

Recordati: Isturisa® (Osilodrostat) Approved In The U.S.

By PRNewswire PRNewswire • 03-09-2020

ARS Pharmaceuticals and Recordati Announce Exclusive License for the Rights in Europe and additional countries for Neffy� (ARS-1; epinephrine nasal spray)

By PRNewswire PRNewswire • 09-22-2020

Recordati Rare Diseases Announce Publication in the Journal of Clinical Endocrinology & Metabolism of the Phase III LINC 4 Study Confirming the Efficacy and Safety of Isturisa� (Osilodrostat) in Patients With Cushing's Disease

By Business Wire Business Wire • 03-29-2022

Recordati Rare Diseases: Isturisa® (osilodrostat) Phase III LINC-4 Trial Meets Its Primary Endpoint in Cushing's Disease

By Business Wire Business Wire • 06-17-2020

Recordati Rare Diseases Announces First European Launch of Isturisa® (osilodrostat)

By Business Wire Business Wire • 06-02-2020

Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa� (Osilodrostat) in Patients With Cushing's Disease in the European Journal of Endocrinology

By Business Wire Business Wire • 08-31-2022

Isturisa® Is Now Available as a Medical Treatment for Cushing's Syndrome in Germany

By Business Wire Business Wire • 07-16-2020